APUS vs CB · $2.4M cap vs P/E 14, rev $59.40B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
APUS currently screens at market cap $2.4M. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the APUS and CB stock pages for the full models.
Not investment advice.